OCTAVA, NCT05732805: A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma |
|
|
| Recruiting | 3 | 270 | RoW | BCD-217, nurulimab+prolgolimab, BCD-100, prolgolimab, Forteca, Placebo | Biocad | Melanoma, Melanoma (Skin), Melanoma Stage III, Melanoma Stage IV, Melanoma Unresectable, Melanoma Metastatic, Melanoma Advanced | 04/24 | 04/25 | | |
NEO-MIMAJOR, NCT05751928: A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma |
|
|
| Recruiting | 3 | 410 | RoW | BCD-217, nurulimab+prolgolimab, anti-PD1, Excision of the primary lesion, Regional lymphadenectomy | Biocad | Melanoma Stage III, Melanoma (Skin) | 01/27 | 06/27 | | |
OBERTON, NCT03913923: Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma |
|
|
| Active, not recruiting | 2 | 117 | RoW | BCD-217, BCD-100, Placebo | Biocad | Melanoma, Melanoma Metastatic | 07/23 | 12/23 | | |